A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly’s Byetta. So-called GLP-1 drugs like Byetta — and similar products being developed by firms including Novo Nordisk and Roche — are seen as a promising new way to fight the growing problem of diabetes, which is closely linked to obesity.
This is the first I have heard of these concerns. Byetta is a drug used to treat type 2 diabetes and is also known to help persons shed a lot …read more

This is an update post to my articles over the last month. I have truly enjoyed writing for Diabetes Notes. It has given me the opportunity to research a topic that affects my everyday life as well as work on my writing skills. I have also had a valid excuse to go downstairs and “hide” on the computer, which is always a welcome break.
Diabetes Alert Day – Diabetes Alert Day is tomorrow, Tuesday the 27th of March. The goal of this day is to raise awareness of diabetes. As I said in my earlier post, …read more

I have something cool to share…. but it has to wait till tomorrow!!! It is about an unnamed drug (hint, I wrote about it yesterday) and an interview with an undisclosed television actress. I can tell you one thing though, it is about diabetes. I know, I am leading you on. I hope you will check back in tomorrow, I am watching you! LOL!

Type 2 diabetics now have another choice when it comes to their treatment. Along with the multiple choices of oral medication, a new injectable drug is now FDA approved and being prescribed. Being a type 2 diabetic myself, I can honestly say I would not be interested in another needle or two throughout the day. My fingers will thank me later! But for some diabetics, BYEETA has been the answer to their disease happiness.

Patients receiving BYETTA achieved a significant A1C reduction of 1.2% at Week 30 and 1.1% at 2.5 years1
Patients with a baseline A1C of …read more